Daily Heralds – Purdue Pharma, the controversial maker of OxyContin, and eyecare-pharmaceutical firm Ocular Therapeutix has announced a research partnership aiming to develop non-opioid pain treatments.
Stamford Advocate– The executive suing Point72 Asset Management for alleged gender discrimination and the Stamford-based firm have agreed to have her case dismissed in court and decided by a private arbitrator, according to documents filed in the past week.
My San Antonio– Purdue Pharma announced Tuesday a corporate turnaround specialist as its new board chairman and also changed its top lawyer, marking the latest in a series of organizational shifts for the embattled maker of the OxyContin opioid.
News Times– Purdue Pharma and other prescription-drug makers and distributors are being sued in five states for private health-insurance costs allegedly spiked by the opioid crisis, in what the plaintiffs’ lawyers describe as unique litigation.
PR Newswire– In lead-up to GDPR’s looming May 25, 2018 deadline, Neo4j, the market leader in connected data, is urging any company that is investing in GDPR compliance to use those investments for a long-term, strategic advantage. As part of that effort, Neo4j is offering an interactive, personalized demonstration and solution assessment, which shows organizations how to use connected data to meet GDPR compliance, and also how to turn those compliance investments into a strategic advantage.
My San Antonio– The U.S. Department of Justice announced this week it would seek reimbursement from Purdue Pharma and other makers of prescription narcotics for federal health and law-enforcement costs incurred from the opioid crisis.
News Times– OxyContin maker Purdue Pharma ranked as the top donor among a group of five pharmaceutical companies that poured millions of dollars during the past five years into prominent nonprofits supporting large-scale opioid use, according to a new report from U.S. Sen. Claire McCaskill.
Stamford Advocate– A growing number of prosecutors and politicians accuse Purdue Pharma of fueling the national opioid crisis. The maker of the maligned opioid OxyContin says there is another side to the story.